Phaseline

Targets › NOS2

NOS2 (Nitric oxide synthase, inducible): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Psychiatry, Genitourinary, Oncology; next expected readout Dec 2026.

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. (UniProt, P35228)

Open in Phaseline: the race on NOS2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas at ArlingtonL-Arginine
Substrate for nitric oxide synthase; overcomes ADMA inhibition to restore NO production an
NOS1, NOS2, NOS3Phase 4Chronic Kidney DiseaseDec 2026
The Methodist Hospital Research InstituteTilarginine
Nitric oxide synthase inhibitor
NOS1, NOS2, NOS3Phase 2HER2-negative Breast CancerDec 2026
German University in CairoL-Arginine
Nitric oxide synthase substrate; enhances NO production to improve vascular function and c
NOS2, NOS3Phase 2Cognition Disorders in Old Age–
Louis MessinaL-Arginine
Substrate for nitric oxide synthase, increases nitric oxide production
NOS1, NOS2, NOS3Phase 1Claudication, IntermittentJul 2027

Conditions

Cognition Disorders in Old Age (1) Chronic Kidney Disease (1) HER2-negative Breast Cancer (1) Claudication, Intermittent (1)

Modalities

small molecule (3)

Companies

German University in Cairo (1) The University of Texas at Arlington (1) The Methodist Hospital Research Institute (1) Louis Messina (1)

Related targets

NOS3 (4) NOS1 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.